Clinical comparability and European biosimilar regulations

Nature Biotechnology

Volumn 28, Issue 1, 2010, Pages 28-31

  Schellekens, Huub ^a   Moors, Ellen ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABSEAMED; BIOGRASTIM; BIOSIMILAR; FILGRASTIM HEXAL; GROWTH HORMONE; HUMAN GROWTH HORMONE; RATIOGRASTIM; RATIOPHARM; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; SILAP; TEVAGRASTIM; UNCLASSIFIED DRUG; ZARZIO;

CLINICAL TRIAL; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EUROPEAN UNION; HEALTH CARE POLICY; HUMAN; NOTE; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BIOPHARMACEUTICS; DRUG EVALUATION, PRECLINICAL; DRUG RECALLS; EUROPE; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG;

EID: 74049092678     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0110-28     Document Type: Note

References (33)

1. Avidor, Y., Mabjeesh, N.J. & Matzkin, H. South Med. J. 96, 1174-1186 (2003).
2. European Parliament and Council. Off. J. Eur. Union 47, 34-57 (2004).
3. Anonymous. Guideline on similar biological medicinal products. (EMEA, London, 2005; accessed 4 March 2008). http://www.emea.europa.eu/pdfs/human/ biosimilar/043704en.pdf
4. Anonymous. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. (EMEA, London, 2006; accessed 4 March 2008).
5. Anonymous. ANNEX to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues guidance on similar medicinal products containing recombinant erythropoietins. (EMEA, London, 2006; accessed 4 March 2008).
6. Anonymous. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues guidance on similar medicinal products containing somatropin. (EMEA, London, 2006; accessed 4 March 2008). http://www.emea.europa.eu/pdfs/ human/biosimilar/9452805en.pdf
7. Anonymous. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues guidance on similar medicinal products containing recombinant human soluble insulin. (EMEA, London, 2006; accessed 4 March 2008).
8. Anonymous. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. (EMEA, London, 2006; accessed 4 March 2008).
9. http://www.patentdocs.org/2009/12/followon-biologics-news-briefs-no-10. html Similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues CHMP/42832/05 http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf Accessed 21 December 2009
10. Crommelin, D.J. et al. Eur. J. Hosp. Pharm. Sci. 1, 11-17 (2005).
11. Roger, S.D. Nephrology 11, 341-346 (2006).
12. Schellekens, H. Nephrol. Dial. Transplant. 20, 31-36 (2005).
13. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/Omnitrope/ H-607-PI-en.pdf〉 (Accessed 4 March 2008)
14. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/valtropin/ H-602-PI-en.pdf〉 (Accessed 4 March 2008)
15. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/abseamed/H-727-en6. pdf〉 (Accessed 4 March 2008)
16. http://www.emea.europa.eu/humandocs/PDFs/EPAR/binocrit/H-725-en6.pdf
17. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/epoetinalfahexal/ H-726-en6.pdf〉 (Accessed 4 March 2008)
18. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-PI-en. pdf〉 (Accessed 4 March 2008)
19. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/retacrit/H-872-en6. pdf〉 (Accessed 4 March 2008)
20. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/Omnitrope/060706en6. pdf〉 (Accessed 4 March 2008)
21. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/valtropin/H-602-en6. pdf〉 (Accessed 4 March 2008)
22. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/Omnitrope/060706en6. pdf〉 (Accessed 4 March 2008)
23. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/valtropin/H-602-en6. pdf〉 (Accessed 4 March 2008)
24. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/epoetinalfahexal/ H-726-en6.pdf〉 (Accessed 4 March 2008)
25. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/binocrit/H-725-en6. pdf〉
26. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/abseamed/H-727-en6. pdf〉 (Accessed 4 March 2008)
27. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-en6. pdf〉 (Accessed 4 March 2008)
28. 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/retacrit/H-872-en6. pdf〉 (Accessed 4 March 2008)
29. Anonymous. CHMP assessment report for Filgrastim Hexal (EMEA, London; 2008) 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/FilgrastimHexal/H-918- en6.pdf〉 (Accessed 28 February 2009)
30. Anonymous. Questions and answers on recommendation for refusal of marketing application for alpheon. (EMEA, London, 2006; accessed 3 March 2008). 〈http://www.emea.europa.eu/pdfs/human/opinion/19089606en.pdf〉
31. Anonymous. Questions and answers on the withdrawal of the marketing authorisation application for Insulin Human Rapid Marvel; Insulin Human Long Marvel; Insulin Human 30/70 Mix Marvel. (EMEA, London; 2008; accessed 28 February 2008). 〈http://www.emea.europa.eu/humandocs/PDFs/EPAR/ insulinhumanrapidmarvel/419308en.pdf〉
32. Blanchette, F. & Neuhaus, O. J. Neurol. 255 Suppl 1, 26-36 (2008).
33. Toblli, J.E., Cao, G., Oliveri, L. & Angerosa., M. Port. J. Nephrol. Hypert. 23, 53-63 (2009).